Get started
CORBUS PHARMACEUTICALS HOLDINGS IN COM USD0.0001(POST REV SPLIT)CORBUS PHARMACEUTICALS HOLDINGS IN COM USD0.0001(POST REV SPLIT)CORBUS PHARMACEUTICALS HOLDINGS IN COM USD0.0001(POST REV SPLIT)

CORBUS PHARMACEUTICALS HOLDINGS IN COM USD0.0001(POST REV SPLIT)

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

0SZI chart


Full chart

0SZI upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪158.33 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−4.7 USD
Net income (FY)
‪−44.60 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪10.89 M‬
Beta (1Y)
2.53

Employees


Employees (FY)
19
Change (1Y)
−14 −42.42%
Revenue / Employee (1Y)
0.00 USD
Net income / Employee (1Y)
‪−2.35 M‬ USD

About Corbus Pharmaceuticals Holdings, Inc.


Sector
Health Technology
CEO
Yuval Cohen
Headquarters
Norwood
Website
corbuspharma.com
Founded
2009
FIGI
BBG00LG7JS80
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

0SZI news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Sparks


Curated watchlists where 0SZI is featured.

See all sparks 

Frequently Asked Questions


The current price of 0SZI is 13.3 USD — it has increased by 0.53% in the past 24 hours. Watch CORBUS PHARMACEUTICALS HOLDINGS IN COM USD0.0001(POST REV SPLIT) stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange CORBUS PHARMACEUTICALS HOLDINGS IN COM USD0.0001(POST REV SPLIT) stocks are traded under the ticker 0SZI.
0SZI stock has fallen by −11.36% compared to the previous week, the month change is a −17.50% fall, over the last year CORBUS PHARMACEUTICALS HOLDINGS IN COM USD0.0001(POST REV SPLIT) has showed a 150.19% increase.
We've gathered analysts' opinions on CORBUS PHARMACEUTICALS HOLDINGS IN COM USD0.0001(POST REV SPLIT) future price: according to them, 0SZI price has a max estimate of 75.00 USD and a min estimate of 35.00 USD. Watch 0SZI chart and read a more detailed CORBUS PHARMACEUTICALS HOLDINGS IN COM USD0.0001(POST REV SPLIT) stock forecast: see what analysts think of CORBUS PHARMACEUTICALS HOLDINGS IN COM USD0.0001(POST REV SPLIT) and suggest that you do with its stocks.
0SZI reached its all-time high on Feb 19, 2019 with the price of 263.7 USD, and its all-time low was 2.2 USD and was reached on Mar 13, 2023. View more price dynamics on 0SZI chart.
See other stocks reaching their highest and lowest prices.
0SZI stock is 3.22% volatile and has beta coefficient of 2.53. Track CORBUS PHARMACEUTICALS HOLDINGS IN COM USD0.0001(POST REV SPLIT) stock price on the chart and check out the list of the most volatile stocks — is CORBUS PHARMACEUTICALS HOLDINGS IN COM USD0.0001(POST REV SPLIT) there?
Today CORBUS PHARMACEUTICALS HOLDINGS IN COM USD0.0001(POST REV SPLIT) has the market capitalization of ‪158.33 M‬, it has decreased by −9.73% over the last week.
Yes, you can track CORBUS PHARMACEUTICALS HOLDINGS IN COM USD0.0001(POST REV SPLIT) financials in yearly and quarterly reports right on TradingView.
CORBUS PHARMACEUTICALS HOLDINGS IN COM USD0.0001(POST REV SPLIT) is going to release the next earnings report on Mar 18, 2025. Keep track of upcoming events with our Earnings Calendar.
0SZI earnings for the last quarter are −1.15 USD per share, whereas the estimation was −0.95 USD resulting in a −20.81% surprise. The estimated earnings for the next quarter are −1.24 USD per share. See more details about CORBUS PHARMACEUTICALS HOLDINGS IN COM USD0.0001(POST REV SPLIT) earnings.
CORBUS PHARMACEUTICALS HOLDINGS IN COM USD0.0001(POST REV SPLIT) revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
0SZI net income for the last quarter is ‪−13.78 M‬ USD, while the quarter before that showed ‪−10.00 M‬ USD of net income which accounts for −37.87% change. Track more CORBUS PHARMACEUTICALS HOLDINGS IN COM USD0.0001(POST REV SPLIT) financial stats to get the full picture.
No, 0SZI doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 22, 2024, the company has 19.00 employees. See our rating of the largest employees — is CORBUS PHARMACEUTICALS HOLDINGS IN COM USD0.0001(POST REV SPLIT) on this list?
Like other stocks, 0SZI shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CORBUS PHARMACEUTICALS HOLDINGS IN COM USD0.0001(POST REV SPLIT) stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CORBUS PHARMACEUTICALS HOLDINGS IN COM USD0.0001(POST REV SPLIT) technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CORBUS PHARMACEUTICALS HOLDINGS IN COM USD0.0001(POST REV SPLIT) stock shows the sell signal. See more of CORBUS PHARMACEUTICALS HOLDINGS IN COM USD0.0001(POST REV SPLIT) technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.